Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials

被引:1042
作者
Early Breast Cancer Trialists' Collaborative Group
机构
[1] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England
关键词
D O I
10.1016/S0140-6736(00)02263-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The long-term effects of radiotherapy on mortality from breast cancer and other causes remain uncertain. Methods A meta-analysis was done of 10-year and 20-year results from 40 unconfounded randomised trials of radiotherapy for early breast cancer. It involved central review of individual patients' data on recurrence and cause-specific mortality from 20 000 women, half with "node-positive" disease. Radiotherapy Fields generally included not only chest wall (or breast) but also axillary, supraclavicular, and internal mammary nodes. Findings A reduction of approximately two-thirds in local recurrence was seen in all trials, largely independent of the type of patient or type of radiotherapy (8.8% vs 27.2% local recurrence by year 10). Hence, to assess effects on breast cancer mortality of substantially better local control, results from all trials were combined. Breast cancer mortality was reduced (2p=0.0001) but other, particularly vascular, mortality was increased (2p=0.0003), and overall 20-year survival was 37.1% with radiotherapy versus 35.9% control (2p=0.06). There was little effect on early deaths, but logrank analyses of later deaths indicate that, on average after year 2, radiotherapy reduced annual mortality rates from breast cancer by 13.2% (SE 2.5) but increased those from other causes by 21.2% (SE 5.4). Nodal status, age, and decade of follow-up strongly affected the ratio of breast cancer mortality to other mortality, and hence affected the ratio of absolute benefit to absolute hazard from these proportional changes in mortality. Interpretation Radiotherapy regimens able to produce the two-thirds reduction in local recurrence seen in these trials, but without long-term hazard, would be expected to produce an absolute increase in 20-year survival of about 2-4% (except for women at particularly low risk of local recurrence). The average hazard seen in these trials would, however, reduce this 20-year survival benefit in young women and reverse it in older women.
引用
收藏
页码:1757 / 1770
页数:14
相关论文
共 22 条
  • [1] ABE O, 1992, LANCET, V339, P71
  • [2] ABE O, 1995, NEW ENGL J MED, V333, P1444
  • [3] Abe O, 1998, LANCET, V352, P930
  • [4] [Anonymous], 1996, Lancet, V348, P1189
  • [5] [Anonymous], 1988, NEW ENGL J MED, V319, P1681
  • [6] [Anonymous], 1990, TREATM EARL BREAST C
  • [7] Burdett S, 1998, LANCET, V352, P257
  • [8] Clarke M, 1998, LANCET, V351, P1451
  • [9] CUZICK J, 1987, CANCER TREAT REP, V71, P15
  • [10] CAUSE-SPECIFIC MORTALITY IN LONG-TERM SURVIVORS OF BREAST-CANCER WHO PARTICIPATED IN TRIALS OF RADIOTHERAPY
    CUZICK, J
    STEWART, H
    RUTQVIST, L
    HOUGHTON, J
    EDWARDS, R
    REDMOND, C
    PETO, R
    BAUM, M
    FISHER, B
    HOST, H
    LYTHGOE, J
    RIBEIRO, G
    SCHEURLEN, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) : 447 - 453